Mattes Hollnagel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mattes Hollnagel has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Christian Peifer
Department of Pharmaceutical Chemistry, Christian-Albrechts-University, Germany
2 shared publications - Gopal P. Sapkota
MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Sir James Black Centre, Dow Street, Dundee, DD1 5EH, United Kingdom
2 shared publications - Lorraine Glennie
MRC Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, School of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, UK
2 shared publications - Malte Arnold
Institute of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry, Christian-Albrechts-University of Kiel, 24118 Kiel, Germany
2 shared publications - Temi Thompson
MRC Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, School of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, UK
2 shared publications
Latest Publications
- Open Access
Design and Synthesis of Novel Candidate CK1δ Proteolysis Targeting Chimeras (PROTACs)
The dysregulation of CK1 isoforms is linked to various types of diseases, including neurodegeneration and different types of neoplasia such as colon, pancreatic, breast, and ovarian cancer. For CK1 isoforms, a plethora of effective small molecule inhibitors are available. However, only a few degraders of CK1α and, more recently, proteolysis targeting chimeras (PROTACs) for CK1δ/CK1ε have been reported. In this study, we applied the PROTAC concept by harnessing molecular modelling to design and synthesize a series of candidate CK1δ-targeting PROTACs based on a highly specific and potent benzothiazole-based CK1δ inhibitor that we previously developed in our lab. In the present study, we established a modular synthetic platform to systematically generate a set of PROTAC degrader candidates consisting of the CK1δ-specific inhibitor scaffold, alkyl and PEG linker motifs with various lengths, and Cereblon (CRBN)-engaging pomalidomide and thalidomide derivatives as E3 ligase binders. We demonstrate that several PROTACs degrade CK1δ/ε in various cells. The most potent PROTAC P1d inhibits the phosphorylation of downstream substrates through CK1δ/ε degradation. We establish the requirement of CUL4ACRBN and the proteasome for the P1d-mediated degradation of CK1δ/ε.
Open AccessDesign and Synthesis of Novel Candidate CK1δ Proteolysis Targeting Chimeras (PROTACs)
The dysregulation of CK1 isoforms is linked to various types of diseases, including neurodegeneration and different types of neoplasia such as colon, pancreatic, breast, and ovarian cancer. For CK1 isoforms, a plethora of effective small molecule inhibitors are available. However, only a few degraders of CK1α and, more recently, proteolysis targeting chimeras (PROTACs) for CK1δ/CK1ε have been reported. In this study, we applied the PROTAC concept by harnessing molecular modelling to design and synthesize a series of candidate CK1δ-targeting PROTACs based on a highly specific and potent benzothiazole-based CK1δ inhibitor that we previously developed in our lab. In the present study, we established a modular synthetic platform to systematically generate a set of PROTAC degrader candidates consisting of the CK1δ-specific inhibitor scaffold, alkyl and PEG linker motifs with various lengths, and Cereblon (CRBN)-engaging pomalidomide and thalidomide derivatives as E3 ligase binders. We demonstrate that several PROTACs degrade CK1δ/ε in various cells. The most potent PROTAC P1d inhibits the phosphorylation of downstream substrates through CK1δ/ε degradation. We establish the requirement of CUL4ACRBN and the proteasome for the P1d-mediated degradation of CK1δ/ε.
- Open Access
- 31 October 2025
- Published by MDPI AG in Preprints.org
Design and Synthesis of Novel Candidate CK1δ Proteolysis Targeting Chimeras (PROTACs)
Dysregulation of CK1 isoforms is linked to various types of diseases, including neuro-degeneration and different types of neoplasia such as colon-, pancreatic-, breast-, and ovarian cancer. For CK1 isoforms, a plethora of effective small molecule inhibitors are available. However, only a few degraders of CK1α and, more recently, PROteolysis TArgeting Chimeras (PROTACs) for CK1δ/CK1ε have been reported. In this study, we applied the PROTAC concept by harnessing molecular modeling to design and synthe-size a series of candidate CK1δ-targeting PROTACs based on a highly specific and po-tent benzothiazole-based CK1δ-inhibitor that we previously developed in our lab. In the present study, we established a modular synthetic platform to systematically gen-erate a set of PROTAC degrader candidates consisting of the CK1δ-specific inhibitor scaffold, alkyl- and PEG-linker motifs with various lengths, and Cereblon (CRBN)-engaging pomalidomide and thalidomide derivatives as E3 ligase binders. We demonstrate that several PROTACs degrade CK1δ/ε in various cells. The most potent PROTAC P1d inhibits the phosphorylation of downstream substrates through CK1δ/ε degradation. We establish the requirement of CUL4ACRBN and the proteasome for P1d-mediated degradation of CK1δ/ε.
- 31 October 2025
- Published by MDPI AG in Preprints.org
Open AccessDesign and Synthesis of Novel Candidate CK1δ Proteolysis Targeting Chimeras (PROTACs)
Dysregulation of CK1 isoforms is linked to various types of diseases, including neuro-degeneration and different types of neoplasia such as colon-, pancreatic-, breast-, and ovarian cancer. For CK1 isoforms, a plethora of effective small molecule inhibitors are available. However, only a few degraders of CK1α and, more recently, PROteolysis TArgeting Chimeras (PROTACs) for CK1δ/CK1ε have been reported. In this study, we applied the PROTAC concept by harnessing molecular modeling to design and synthe-size a series of candidate CK1δ-targeting PROTACs based on a highly specific and po-tent benzothiazole-based CK1δ-inhibitor that we previously developed in our lab. In the present study, we established a modular synthetic platform to systematically gen-erate a set of PROTAC degrader candidates consisting of the CK1δ-specific inhibitor scaffold, alkyl- and PEG-linker motifs with various lengths, and Cereblon (CRBN)-engaging pomalidomide and thalidomide derivatives as E3 ligase binders. We demonstrate that several PROTACs degrade CK1δ/ε in various cells. The most potent PROTAC P1d inhibits the phosphorylation of downstream substrates through CK1δ/ε degradation. We establish the requirement of CUL4ACRBN and the proteasome for P1d-mediated degradation of CK1δ/ε.